Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Cancers | Free Full-Text | Lights and Shadows in Immuno-Oncology Drug Development
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
The Radiology Assistant : RECIST 1.1 - and more
The Radiology Assistant : RECIST 1.1 - and more
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
soria on Twitter: "#ENA2016 Dr seymour @theNCI @EORTC @aacr on iRECIST goals and limitations https://t.co/2TBUcpcndq" / Twitter
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,
Présentation PowerPoint
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: how to do it | Cancer Imaging | Full Text
RECIST 1.1 calculator - Radiology calculators
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
How to better understand iRECIST – a new wave in immunotherapeutic
How to better understand iRECIST – a new wave in immunotherapeutic
